The Oncology Institute, Inc. TOI Specialty Pharmacy — Total operating revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s specialty pharmacy — total operating revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s specialty pharmacy — total operating revenue?
- The Oncology Institute, Inc. (TOI) reported specialty pharmacy — total operating revenue of $87.54M in Q1 2026.
- How has The Oncology Institute, Inc.'s specialty pharmacy — total operating revenue changed year-over-year?
- The Oncology Institute, Inc.'s specialty pharmacy — total operating revenue increased by 77.6% year-over-year, from $49.29M to $87.54M.
- What does specialty pharmacy — total operating revenue mean?
- This metric represents the total gross revenue generated from the sale and distribution of specialty pharmaceutical products, including oral and injectable oncology medications. It reflects the scale and market penetration of the company's in-house dispensary operations. Growth in this area indicates successful patient capture and effective management of the pharmaceutical supply chain within the oncology care model.